✦ LIBER ✦

O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer

✍ Scribed by Robinet, G.; Falchero, L.; Perol, M.; Thomas, P.; Monnet, I.; Grivaux, M.; Crequit, J.; Letreut, J.; Paillotin, D.; Chouaid, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line therapy with gefitinib in co

✍ G. Robinet; F. Barlesi; P. Fournel; H. Berard; R. Corre; A. Vergnenegre; L. Falc 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 160 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB

PD-070 SIGN: A Phase II, open-label, ran

✍ Cufer, T.; Vrdoljak, E. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

P-551 A phase II randomized trial of wee

✍ Tsai, Chun-Ming; Chiu, Chao-Hua; Wang, Gwo-Shu; Su, Wei-Juin; Chen, Yuh-Min; Per 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 342 KB

Phase I/II Trial of Docetaxel and Carbop

✍ Kensuke Kataoka; Ryujiro Suzuki; Hiroyuki Taniguchi; Yasunobu Noda; Joe Shindoh; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 82 KB

Results of a phase II multicenter trial

✍ Neubauer, Marcus A.; Garfield, David H.; Kuerfler, Paul R.; Raju, Robert N.; Lin 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 98 KB